

Manlio Ferrarini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5341040/publications.pdf>

Version: 2024-02-01

157
papers

10,866
citations

66343

42
h-index

32842

100
g-index

162
all docs

162
docs citations

162
times ranked

8666
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499.	2.2	5
2	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021, 96, E168-E171.	4.1	10
3	Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients. <i>Cell Reports</i> , 2021, 34, 108845.	6.4	3
4	Validation of the Alternative International Prognostic Score (AIPSA): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-CISL protocol. <i>European Journal of Haematology</i> , 2021, 106, 831-835.	2.2	6
5	TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021, 96, E306-E310.	4.1	8
6	Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. <i>American Journal of Hematology</i> , 2021, 96, E269-E272.	4.1	3
7	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 684621.	2.8	6
8	Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?. <i>Cells</i> , 2021, 10, 98.	4.1	23
9	Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: role of TNF α , IL-6 and IL-11 cytokines. <i>Haematologica</i> , 2021, 106, 2598-2612.	3.5	9
10	Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?. <i>Frontiers in Oncology</i> , 2020, 10, 593383.	2.8	50
11	Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients. <i>Scientific Reports</i> , 2020, 10, 18427.	3.3	13
12	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. <i>Blood Cancer Journal</i> , 2020, 10, 92.	6.2	7
13	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	1.4	86
14	TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 869-880.	4.1	10
15	NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespective of Cytogenetic Groups or Clinical Outcome. <i>Non-coding RNA</i> , 2020, 6, 11.	2.6	11
16	Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach. <i>Molecular Medicine</i> , 2020, 26, 25.	4.4	17
17	Optimization of a WGA-Free Molecular Tagging-Based NGS Protocol for CTCs Mutational Profiling. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4364.	4.1	4
18	Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , 2020, 38, 406-408.	1.7	5

#	ARTICLE	IF	CITATIONS
19	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1613-1620.	3.5	15
20	Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients. <i>Molecular Medicine</i> , 2019, 25, 15.	4.4	22
21	Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations. <i>Journal of Pathology</i> , 2019, 247, 416-421.	4.5	25
22	Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	13
23	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. <i>American Journal of Hematology</i> , 2018, 93, E216-E219.	4.1	15
24	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter Oâ€œCLLâ€œâ€œGISLâ€œ study. <i>European Journal of Haematology</i> , 2016, 96, 36-45.	2.2	7
25	A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI). <i>Clinical Immunology</i> , 2016, 172, 52-60.	3.2	4
26	A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2016, 30, 1440-1443.	7.2	28
27	Alliance Against Cancer, the network of Italian cancer centers bridging research and care. <i>Journal of Translational Medicine</i> , 2015, 13, 360.	4.4	10
28	Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia Cells. <i>PLoS ONE</i> , 2015, 10, e0134706.	2.5	16
29	The OECl Certification/Designation Program: The Genoa Experience. <i>Tumori</i> , 2015, 101, S19-S20.	1.1	0
30	Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment. <i>Leukemia Research</i> , 2015, 39, 840-845.	0.8	12
31	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 3150-3158.	1.3	23
32	A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes. <i>Immunologic Research</i> , 2015, 63, 90-100.	2.9	18
33	Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study. <i>British Journal of Haematology</i> , 2015, 168, 455-459.	2.5	9
34	Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukaemia. <i>PLoS ONE</i> , 2015, 10, e0118801.	2.5	15
35	Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter Oâ€œCLLâ€œâ€œGISLâ€œ study. <i>American Journal of Hematology</i> , 2014, 89, 743-750.	4.1	14
36	Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 264-273.	2.8	10

#	ARTICLE	IF	CITATIONS
37	High-throughput sequencing for the identification of <i>NOTCH1</i> mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. British Journal of Haematology, 2014, 165, 629-639.	2.5	52
38	Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2014, 53, 612-621.	2.8	38
39	microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters. Clinical Cancer Research, 2014, 20, 4141-4153.	7.0	52
40	Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. Haematologica, 2014, 99, 1078-1087.	3.5	43
41	miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease. Journal of Cellular Physiology, 2013, 228, 1506-1515.	4.1	156
42	Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. BMC Medical Genomics, 2013, 6, 27.	1.5	73
43	Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter OCLLCISL study. American Journal of Hematology, 2013, 88, 539-544.	4.1	10
44	Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 24-31.	4.1	27
45	The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: Results of a comparative analysis. Leukemia Research, 2013, 37, 943-947.	0.8	9
46	Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features. Clinical Cancer Research, 2013, 19, 5890-5900.	7.0	60
47	Igs Expressed by Chronic Lymphocytic Leukemia B Cells Show Limited Binding-Site Structure Variability. Journal of Immunology, 2013, 190, 5771-5778.	0.8	21
48	Expression of Immunoglobulin Receptors with Distinctive Features Indicating Antigen Selection by Marginal Zone B Cells from Human Spleen. Molecular Medicine, 2013, 19, 294-302.	4.4	16
49	Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers. Tumori, 2013, 99, 293e-8e.	1.1	3
50	Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: <i>In Vitro</i> and <i>In Vivo</i> Evidence. Clinical Cancer Research, 2012, 18, 6260-6270.	7.0	213
51	Seasonal and pandemic (A/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens. Blood, 2012, 120, 1954-1957.	1.4	16
52	Low Percentage of KRAS Mutations Revealed by Locked Nucleic Acid Polymerase Chain Reaction: Implications for Treatment of Metastatic Colorectal Cancer. Molecular Medicine, 2012, 18, 1519-1526.	4.4	24
53	Intraclonal Cell Expansion and Selection Driven by B Cell Receptor in Chronic Lymphocytic Leukemia. Molecular Medicine, 2011, 17, 834-839.	4.4	9
54	Mutation Pattern of Paired Immunoglobulin Heavy and Light Variable Domains in Chronic Lymphocytic Leukemia B Cells. Molecular Medicine, 2011, 17, 1188-1195.	4.4	11

#	ARTICLE	IF	CITATIONS
55	Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of Chronic Lymphocytic Leukemia. PLoS ONE, 2011, 6, e24313.	2.5	36
56	Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood, 2011, 117, 1781-1791.	1.4	230
57	The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood, 2011, 118, 6353-6361.	1.4	45
58	CD38 and chronic lymphocytic leukemia: a decade later. Blood, 2011, 118, 3470-3478.	1.4	181
59	Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in Chronic lymphocytic leukemia: A comparative study. Genes Chromosomes and Cancer, 2011, 50, 726-734.	2.8	24
60	Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. Epigenetics, 2011, 6, 188-194.	2.7	58
61	Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin's Lymphoma Patients Treated with Rituximab-Containing Regimens. Journal of Immunology, 2011, 186, 6044-6055.	0.8	93
62	Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era. International Journal of Hematology, 2010, 91, 342-344.	1.6	6
63	Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells. Experimental Hematology, 2010, 38, 373-383.	0.4	22
64	Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. European Journal of Haematology, 2010, 85, 314-320.	2.2	23
65	Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience. Leukemia Research, 2010, 34, e217-e218.	0.8	3
66	More on the determination of Ki-67 as a novel potential prognostic marker in B-cell chronic lymphocytic leukemia. Leukemia Research, 2010, 34, e326-e328.	0.8	2
67	Prognostic relevance of <i>in vitro</i> response to cell stimulation via surface IgD in binet stage a CLL. British Journal of Haematology, 2010, 149, 160-163.	2.5	17
68	Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion. Clinical Cancer Research, 2010, 16, 5641-5653.	7.0	52
69	Serum level of CD26 predicts time to first treatment in early B-cell chronic lymphocytic leukemia. European Journal of Haematology, 2009, 83, 208-214.	2.2	8
70	CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL. Hematological Oncology, 2009, 27, 140-147.	1.7	46
71	Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. British Journal of Haematology, 2009, 146, 44-53.	2.5	50
72	PNAE1/4 can significantly reduce Burkitt's lymphoma tumor burden in a SCID mice model: cells dissemination similar to the human disease. Cancer Gene Therapy, 2009, 16, 786-793.	4.6	10

#	ARTICLE	IF	CITATIONS
73	Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2009, 33, 162-165.	0.8	16
74	Predictive value of \hat{A}^2 -microglobulin (\hat{A}^2 -m) levels in chronic lymphocytic leukemia since Binet A stages. <i>Haematologica</i> , 2009, 94, 887-888.	3.5	37
75	Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia. <i>International Journal of Hematology</i> , 2008, 88, 374-380.	1.6	12
76	Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 781-793.	2.8	59
77	Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 62-67.	1.3	4
78	The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. <i>Blood</i> , 2008, 111, 517-524.	1.4	104
79	Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells. <i>Haematologica</i> , 2008, 93, 413-422.	3.5	42
80	Origin and Nature of Chronic Lymphocytic Leukemia B Cells. , 2008, , 1-18.		1
81	B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens. <i>Journal of Clinical Pathology</i> , 2007, 60, 627-632.	2.0	6
82	The Peptide Nucleic Acid Targeted to a Regulatory Sequence of the Translocated c-myc Oncogene in Burkitt's Lymphoma Lacks Immunogenicity: Follow-Up Characterization of PNAE1/4-NLS. Oligonucleotides, 2007, 17, 146-150.	2.7	22
83	CD5 ⁺ B cells with the features of subepithelial B cells found in human tonsils. <i>European Journal of Immunology</i> , 2007, 37, 2138-2147.	2.9	17
84	Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2007, 31, 1575-1578.	0.8	25
85	Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc. <i>Cancer Gene Therapy</i> , 2007, 14, 220-226.	4.6	37
86	The CD38 Ectoenzyme Family: Advances in Basic Science and Clinical Practice. <i>Molecular Medicine</i> , 2006, 12, 342-344.	4.4	31
87	Similarities and Differences Between the Light and Heavy Chain Ig Variable Region Gene Repertoires in Chronic Lymphocytic Leukemia. <i>Molecular Medicine</i> , 2006, 12, 300-308.	4.4	20
88	Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. <i>Blood</i> , 2006, 107, 3708-3715.	1.4	107
89	B lymphocytes in humans express ZAP-70 when activated in vivo. <i>European Journal of Immunology</i> , 2006, 36, 558-569.	2.9	60
90	Evolving View of the In-Vivo Kinetics of Chronic Lymphocytic Leukemia B Cells. <i>Hematology American Society of Hematology Education Program</i> , 2006, 2006, 273-278.	2.5	25

#	ARTICLE	IF	CITATIONS
91	Definition of a Prognostic Scoring System for Predicting Clinical Outcome in B-Cell Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2328-2328.	1.4	1
92	Immunoglobulin Gene Mutation Patterns and Heterogeneity of Marginal Zone Lymphoma. , 2005, 115, 173-196.		0
93	Therapeutically Promising PNA Complementary to a Regulatory Sequence for c-myc:Pharmacokinetics in an Animal Model of Human Burkitt's Lymphoma. Oligonucleotides, 2005, 15, 85-93.	2.7	29
94	Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2005, 352, 804-815.	27.0	1,443
95	In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. Journal of Clinical Investigation, 2005, 115, 755-764.	8.2	515
96	Multiple Distinct Sets of Stereotyped Antigen Receptors Indicate a Role for Antigen in Promoting Chronic Lymphocytic Leukemia. Journal of Experimental Medicine, 2004, 200, 519-525.	8.5	370
97	Recent advances in the molecular biology and immunobiology of chronic lymphocytic leukemia. Seminars in Hematology, 2004, 41, 207-223.	3.4	32
98	Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood, 2004, 103, 375-382.	1.4	164
99	Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. Journal of Clinical Investigation, 2004, 113, 1008-1016.	8.2	190
100	Maintenance of B lymphocyte-related clones in the cerebrospinal fluid of multiple sclerosis patients. European Journal of Immunology, 2003, 33, 3433-3438.	2.9	39
101	The Human Marginal Zone B Cell. Annals of the New York Academy of Sciences, 2003, 987, 117-124.	3.8	35
102	B CELLCHRONICLYMPHOCYTICLEUKEMIA: Lessons Learned from Studies of the B Cell Antigen Receptor. Annual Review of Immunology, 2003, 21, 841-894.	21.8	319
103	Biology and Treatment of Chronic Lymphocytic Leukemia. Hematology American Society of Hematology Education Program, 2003, 2003, 153-175.	2.5	96
104	Chromosome aberrations evaluated by comparative genomic hybridization in B-cell chronic lymphocytic leukemia: correlation with CD38 expression. Haematologica, 2003, 88, 769-77.	3.5	17
105	Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro. Haematologica, 2003, 88, 864-73.	3.5	16
106	CD10 is a marker for cycling cells with propensity to apoptosis in childhood ALL. British Journal of Cancer, 2002, 86, 1776-1785.	6.4	36
107	Chronic Lymphocytic Leukemia B Cells Can Undergo Somatic Hypermutation and Intracлонаl Immunoglobulin VHDJH Gene Diversification. Journal of Experimental Medicine, 2002, 196, 629-639.	8.5	87
108	B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood, 2002, 99, 4087-4093.	1.4	294

#	ARTICLE	IF	CITATIONS
109	Role of surface IgM and IgD on survival of the cells from B-cell chronic lymphocytic leukemia. Blood, 2002, 99, 2277-2278.	1.4	17
110	Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo. Blood, 2001, 97, 2528-2529.	1.4	23
111	In vitro stimulation of human tonsillar subepithelial B cells: requirement for interaction with activated T cells. European Journal of Immunology, 2001, 31, 752-756.	2.9	13
112	Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming. Nature Medicine, 2001, 7, 807-813.	30.7	88
113	Analysis of stepwise genetic changes in an AIDS-related Burkitt's lymphoma. International Journal of Cancer, 2000, 88, 744-750.	5.1	7
114	Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nature Biotechnology, 2000, 18, 300-303.	17.5	229
115	Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood, 2000, 95, 1199-1206.	1.4	76
116	Heterogeneity of Tonsillar Subepithelial B Lymphocytes, the Splenic Marginal Zone Equivalents. Journal of Immunology, 2000, 164, 5596-5604.	0.8	84
117	Accumulation of Clonally Related B Lymphocytes in the Cerebrospinal Fluid of Multiple Sclerosis Patients. Journal of Immunology, 2000, 164, 2782-2789.	0.8	234
118	Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia. Blood, 1999, 94, 1840-1847.	1.4	2,291
119	Expression of CD10 by Human T Cells That Undergo Apoptosis Both In Vitro and In Vivo. Blood, 1999, 94, 3067-3076.	1.4	66
120	Apoptosis Induced by Crosslinking of CD4 on Activated Human B Cells. Cellular Immunology, 1999, 193, 80-89.	3.0	11
121	Identification of HSP-60 as the specific antigen of IgM produced by BRG-lymphoma cells. Electrophoresis, 1999, 20, 1092-1097.	2.4	2
122	Expression of CD10 by Human T Cells That Undergo Apoptosis Both In Vitro and In Vivo. Blood, 1999, 94, 3067-3076.	1.4	1
123	Phenotypic and Functional Characterization of Human Tonsillar Subepithelial (SE) B Cells. Annals of the New York Academy of Sciences, 1997, 815, 171-181.	3.8	7
124	C-Myc Proto-oncogene Expression by Germinal Center B Cells Isolated from Human Tonsils. Annals of the New York Academy of Sciences, 1997, 815, 436-438.	3.8	3
125	The propensity to apoptosis of centrocytes and centroblasts correlates with elevated levels of intracellular myc protein. European Journal of Immunology, 1997, 27, 234-238.	2.9	23
126	Heterogeneous p53 mutations in a Burkitt lymphoma from an AIDS patient with monoclonal c-myc and VDJ rearrangements. , 1997, 73, 816-821.		6

#	ARTICLE	IF	CITATIONS
127	Analysis of Epstein-Barr virus (EBV) type and variant in spontaneous lymphoblastoid cells and Hu-SCID mouse tumours. <i>Molecular and Cellular Probes</i> , 1996, 10, 453-461.	2.1	7
128	Subepithelial B cells in the human palatine tonsil. I. Morphologic, cytochemical and phenotypic characterization. <i>European Journal of Immunology</i> , 1996, 26, 2035-2042.	2.9	67
129	Subepithelial B cells in the human palatine tonsil. II. Functional characterization. <i>European Journal of Immunology</i> , 1996, 26, 2043-2049.	2.9	33
130	Lymphoblastoid cells transfected with c-myc: Downregulation of EBV-lytic antigens and impaired response of autologous CD4+ T cells in vitro. , 1996, 68, 810-816.		8
131	Production of Inflammatory Cytokines by Epstein-Barr Virus (EBV)-Infected Lymphoblastoid Cell Lines Spontaneously Originated from the Peripheral Blood of Patients with Human Immunodeficiency Virus (HIV) Infection. <i>Clinical Immunology and Immunopathology</i> , 1995, 77, 162-171.	2.0	7
132	Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts. <i>Journal of Experimental Medicine</i> , 1995, 181, 699-711.	8.5	55
133	IgG+, CD5+ Human Chronic Lymphocytic Leukemia B Cells. Production of IgG Antibodies That Exhibit Diminished Autoreactivity and IgG Subclass Skewing. <i>Autoimmunity</i> , 1994, 19, 39-48.	2.6	15
134	CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells. <i>European Journal of Immunology</i> , 1994, 24, 1218-1222.	2.9	151
135	Expression of CD5 and CD38 by human CD5+ B cells: Requirement for special stimuli. <i>European Journal of Immunology</i> , 1994, 24, 1426-1433.	2.9	36
136	HIV-1 Induces Down-Regulation of bcl-2 Expression and Death by Apoptosis of EBV-Immortalized B Cells: A Model for a Persistent "Self-Limiting" HIV-1 Infection. <i>Virology</i> , 1994, 198, 234-244.	2.4	46
137	Identification of two distinct CD5- B cell subsets from human tonsils with different responses to CD40 monoclonal antibody. <i>European Journal of Immunology</i> , 1993, 23, 873-881.	2.9	21
138	Coexpression of Fc γ receptor IIIA and interleukin-2 receptor γ chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes. <i>Journal of Clinical Immunology</i> , 1993, 13, 228-236.	3.8	17
139	Cytogenetic Rearrangement of C-MYC Oncogene Occurs Prior to Infection with Epstein-Barr Virus in the Monoclonal Malignant B Cells From an AIDS Patient. <i>Leukemia and Lymphoma</i> , 1993, 9, 157-164.	1.3	13
140	Production of hematopoietic growth factors by human B lymphocytes: Mechanisms and possible implications. <i>Stem Cells</i> , 1993, 11, 150-155.	3.2	5
141	Evidence for differential responsiveness of human CD5+ and CD5+ B cell subsets to T cell-independent mitogens. <i>European Journal of Immunology</i> , 1991, 21, 351-359.	2.9	35
142	Infection of Epstein-Barr virus-transformed lymphoblastoid B cells by the human immunodeficiency virus: evidence for a persistent and productive infection leading to B cell phenotypic changes. <i>European Journal of Immunology</i> , 1990, 20, 2041-2049.	2.9	34
143	CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors. <i>European Journal of Immunology</i> , 1989, 19, 1037-1044.	2.9	46
144	Xenotransplantation in immunosuppressed nude mice of human solid tumors and acute leukemias directly from patients or in vitro cell lines. <i>Research in Clinical and Laboratory</i> , 1989, 19, 231-43.	0.3	21

#	ARTICLE	IF	CITATIONS
145	Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. American Journal of Medicine, 1988, 84, 240-250.	1.5	87
146	Presence of Activated T-Cells With a T8+ M1+ Leu 7+ Surface Phenotype in Invaded Lymph Nodes From Patients With Solid Tumors ²³ . Journal of the National Cancer Institute, 1986, 77, 637-641.	6.3	14
147	Modulation of neutrophil Fc and C3b receptors. Inflammation, 1983, 7, 155-168.	3.8	11
148	A lymphoproliferative disorder of the large granular lymphocytes with natural killer activity. Journal of Clinical Immunology, 1983, 3, 30-41.	3.8	53
149	A role for natural killer cells in survival: Functions of large granular lymphocytes, including regulation of cell proliferation. Clinical Immunology and Immunopathology, 1983, 29, 323-332.	2.0	27
150	Expression of a receptor for sheep erythrocytes by B lymphocytes from a chronic lymphocytic leukemia patient. Clinical Immunology and Immunopathology, 1983, 27, 210-222.	2.0	7
151	Large Granular Lymphocytes Have a Regulatory Role on the Growth of Human Peripheral Blood T Cell and Erythroid Colonies. Pathology and Immunopathology Research, 1983, 2, 47-56.	0.8	1
152	Human T cell lines with antigen specificity and helper activity. European Journal of Immunology, 1982, 12, 468-474.	2.9	28
153	MORPHOLOGY AND CYTOCHEMISTRY OF HUMAN LARGE GRANULAR LYMPHOCYTES. , 1982, , 1-8.		6
154	COULD HUMAN LARGE GRANULAR LYMPHOCYTES REPRESENT A NEW CELL LINEAGE?. , 1982, , 257-264.		5
155	Ultrastructure and cytochemistry of human peripheral blood lymphocytes. Similarities between the cells of the third population and TG lymphocytes. European Journal of Immunology, 1980, 10, 562-570.	2.9	102
156	Characterization of Human T-Cell Subpopulations as Defined by Specific Receptors for Immunoglobulins. , 1978, 8, 19-53.		125
157	Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements. Frontiers in Oncology, 0, 12, .	2.8	4